drug · protein
cenegermin
Phase 2updated 3mo agoby Dompe Farmaceutici SpA🔗 ChEMBL
Phase 2community read0 votes
Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for keratitis and eye disease and 1 investigational indication.
targets
Neurotrophic tyrosine kinase receptor
all catalysts(0)
nothing on the calendar yet
Trials studying cenegermin
- phase3An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
- phase3Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
- phase3Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease
- phase4Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis
- —Corneal Nerves After Treatment With Cenegermin
- phase4Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis
- phase3Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)
- —OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate
News(1)
- An eye drug biotech banks $118M and stocks its executive suiteClaris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.biopharma_dive · 23d ago
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that